BRAF and metastatic melanoma: Data from a large phase I study with pembrolizumab (Robert et al., 2014a, Robert et al., 2014b) led to its approval by the US Food and Drug Administration (FDA) in September 2014 for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.